Safety and efficacy of dupilumab in rhinosinusitis :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Real world safety and efficacy of dupilumab in people with chronic rhinosinusitis

Chronic rhinosinusitis Chronic rhinosinusitis
Chronic rhinosinusitis Chronic rhinosinusitis

A multicentric, observational, prospective study in real-life aimed to assess safety and effectiveness of dupilumab in adults having severe asthma and CRSwNP graded by common overlapping comorbid situations.

See All

Key take away

In people suffering from severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and related comorbidities, intervention with dupilumab is efficacious and well-tolerated.

Background

A multicentric, observational, prospective study in real-life aimed to assess safety and effectiveness of dupilumab in adults having severe asthma and CRSwNP graded by common overlapping comorbid situations.

Method

In this study, adults (n = 82) with severe CRSwNP who had initiated dupilumab intervention in the context of standard care were recruited. Collection of data was done and several efficacy parameters were utilized. Utilizing the Wilcoxon test for paired data, a comparison of the patient data was done. Using SPSS version 20, all the statistical evaluations were done.

Result

A profound betterment was identified for all applied effectiveness parameters like: (i)  Dermatology Life Quality Index (DLQI) and Eczema Area and Severity Index (EASI) scores for atopic dermatitis, (ii) Asthma Quality of Life Questionnaire (AQLQ) and Forced Expiratory Volume in the 1st second (FEV1) scores for asthma, (iii) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and Rhinitis Control Scoring System (RCSS) scores for allergic perennial rhinitis, and (iv) bilateral endoscopic nasal polyp score (NPS) and 22-item Sino-Nasal Outcome Test (SNOT-22) scores for CRSwNP.

For chronic spontaneous urticaria, an insignificant enhancement was attained in Urticaria Activity Score over 7 days (UAS7). Intervention with dupilumab illustrated good tolerability.

Conclusion

The IgG4 monoclonal antibody dupilumab is effective for the management of people diagnosed with CRSwNP and related comorbidities.

Source:

Clinical and Molecular Allergy

Article:

Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life

Authors:

Eustachio Nettis et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: